EANS-News: Oxygen Biotherapeutics Inc. / Now Marketing New Formulation of Dermacyte Oxygen Concentrate

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Company Information/Marketing/New Products/Biotechnology

Durham, NC (euro adhoc) - Press Release

Oxygen Biotherapeutics Inc.:

Oxygen Biotherapeutics Now Marketing New Formulation of Dermacyte
Oxygen Concentrate

DURHAM, NC —Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) today
announced that the company has begun distribution for its newly
formulated Dermacyte Oxygen Concentrate for the beauty and skin care
market. The over-the-counter product is a scientifically designed
perfluorocarbon concentrate designed to enhance oxygen delivery to
skin. As of later this week, retail orders also can be placed on the
Dermacyte secure website at www.BuyDermacyte.com.

"Inventory of Dermacyte sold out quickly last fall when it was
originally introduced in a market test designed to gauge customer
interest and response," said Chris Stern, company chairman and CEO.
"The feedback we received from customers was quite positive. We´ve
improved the Dermacyte concentrate to be smoother and more effective.
Therefore, we believe that our new cosmetic line has the potential to
be a significant financial contributor to our company."

Dermacyte Oxygen Concentrate is the first product in a broad and
diverse cosmetic line currently under development. It uses the
company´s patented Oxycyte technology, an oxygen carrier
scientifically designed to enhance oxygen delivery to tissues such as
skin. Some potential benefits of increased oxygenation to the skin
include a decrease in the appearance of fine lines, wrinkles and
dryness.

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is dedicated to commercializing
innovative pharmaceuticals and medical devices in the field of oxygen
therapeutics and Defense Medicine. The company has developed a
perfluorocarbon (PFC) therapeutic oxygen carrier and liquid
ventilation product (Oxycyte) and has out-licensed an implantable
glucose sensor. These products are based upon core technologies that
include biomedical applications for PFCs as well as medical and
industrial applications for biosensors. Each of the product
candidates is designed with advantages over currently marketed
products in major markets including traumatic brain injury, sickle
cell crisis, trauma, wound care, decompression sickness, acute
respiratory distress syndrome, stroke, myocardial infarction,
surgery, diabetes wounds and ulcers, and cosmetic applications which
are being marketed under the Dermacyte name. More information is
available at www.oxybiomed.com.

Caution Regarding Forward-Looking Statements.

This news release contains certain forward-looking statements by the
company that involve risks and uncertainties and reflect the
company's judgment as of the date of this release. These statements
include those referring to the plans for the expansion of the
Dermacyte product line and the timing of the introduction of those
new products. Matters beyond the company´s control could lead to
delays in the in the new product introductions and customer
acceptance of these new products. Furthermore, there can be no
assurance that such plans will lead to meaningful sales of Dermacyte
or generate any revenue for the company. The company disclaims any
intent or obligation to update these forward-looking statements
beyond the date of this release. This caution is made under the safe
harbor provisions of the Private Securities Litigation Reform Act of
1995.

DURHAM, NC — March 29, 2010

Links

Homepage: www.oxybiomed.com/
Dermacyte: http://www.buydermacyte.com

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Oxygen Biotherapeutics Inc.
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Ellen Corliss

Oxygen Biotherapeutics, Inc.

2530 Meridian Pkwy, 3rd floor

Durham, NC 27713

Direct Telephone: +1 919 806 4405

Direct Fax: +1 919 806 4417

Email: e.corliss@oxybiomed.com

Branche: Biotechnology
ISIN: US69207P2092
WKN: A0YD9Z
Börsen: New York / Nasdaq